AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NantKwest","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"NantKwest","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid\u2019s Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio\u2019s Expanded Phase 2 Study of Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"NantKwest","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Reports Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Pancreatic Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio\u2019s Novel Immunotherapy NANT Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights Preliminary Results of Cohort C of QUILT 88","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients\u201490% of Patients Have Exceeded Historical Survival Rates to Date","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"CytRx Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"CytRx Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Aldoxorubicin Hydrochloride

    Menu

    Aldoxorubicin Hydrochloride

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

              Details:

              ImmunityBio continues to study the effectiveness of N-803 and aldoxorubicin in combination with PD-L1 thaNK in Phase 1 / 2 clinical trials to treat triple negative breast cancer and head and neck cancer.

              Lead Product(s): Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunityBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Histo...

              Details:

              Phase 2, open-label study will evaluate the comparative efficacy and overall safety of chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic pancreatic cancer.

              Lead Product(s): N-803,Aldoxorubicin HCl,PD-L1 t-haNK

              Therapeutic Area: Oncology Product Name: Anktiva

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunityBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

              Details:

              Phase 2, study will evaluate the comparative efficacy and safety of standard-of-care chemotherapy versus standard-of-care chemotherapy, in combination with PD-L1 t-haNK, Anktiva (N-803), and aldoxorubicin in subjects with locally advanced or metastatic pancreatic cancer.

              Lead Product(s): Aldoxorubicin HCl,Paclitaxel,Gemcitabine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: CytRx Corporation

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights Preliminary Results of Cohort C of QUILT 88

              Details:

              Enrollment of Cohort C, which includes Aldoxorubicin and patients who have previously failed two lines of standard-of-care therapy, is expected to be completed in the third quarter of 2021 and an early readout of survival data is expected in the first quarter of 2022.

              Lead Product(s): Aldoxorubicin HCl,Paclitaxel,Avelumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunityBio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine

              Details:

              T cell activation can then be enhanced further by infusion of the company’s proprietary, off-the-shelf, natural killer cell platform and its IL-15 superagonist N-803 (Anktiva).

              Lead Product(s): N-803,Aldoxorubicin HCl,PD-L1 t-haNK

              Therapeutic Area: Oncology Product Name: Anktiva

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Reports Use of Aldoxorubicin in Phase 2 Clinical Trials Yielding Positive Interim Data on Survival Rates in Pancreatic Cancer Patients

              Details:

              NantKwest and ImmunityBio’s QUILT 88 Trial shows novel combination immunotherapy, which includes which include CytRx’s licensed drug aldoxorubicin, has more than doubled historic median survival rates in patients.

              Lead Product(s): Aldoxorubicin HCl,PD-L1 t-haNK,Paclitaxel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: NantKwest

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NantKwest

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Immunitybio and Nantkwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company

              Details:

              The transaction is structured as a tax-free 100% stock-for-stock merger, with ImmunityBio to reverse merge with NantKwest. Following the closing of the transaction, the combined company will assume the ImmunityBio name and continue to be listed on the NASDAQ exchange.

              Lead Product(s): Aldoxorubicin HCl,N-803,PD-L1 t-haNK

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger December 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio’s Expanded Phase 2 Study of Pancreatic Cancer Treatment

              Details:

              Third-Line cohort added to Phase 2 pancreatic cancer trial for combination immunotherapy that includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK.

              Lead Product(s): PD-L1 t-haNK,N-803,Aldoxorubicin HCl

              Therapeutic Area: Oncology Product Name: PD-L1 t-haNK

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              CytRx Corporation

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer

              Details:

              CytRx highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio, Inc. and NantKwest, Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer.

              Lead Product(s): PD-L1 t-haNK,N-803,Aldoxorubicin HCl

              Therapeutic Area: Oncology Product Name: PD-L1 t-haNK

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NantKwest

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NantKwest, ImmunityBio Add Third-Line Cohort to Phase 2 Pancreatic Cancer Trial

              Details:

              Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist AnktivaÔ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer.

              Lead Product(s): PD-L1 t-haNK,N-803,Aldoxorubicin HCl

              Therapeutic Area: Oncology Product Name: PD-L1 t-haNK

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: ImmunityBio

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY